Why Florida wants companies to turn over personal data about customers' prescriptions
The Office of Insurance Regulation is demanding the unusual trove of data from pharmacy benefit managers — health care industry middlemen that Gov. Ron DeSantis and others have blamed for skyrocketing drug prices and monopolistic behavior.
The companies were asked this year to turn over claim reimbursement data for every prescription drug they filled in Florida in 2024, possibly hundreds of millions of transactions.
The state did not answer when asked how many companies have complied. It said it wanted the data to better understand the companies' practices.
Industry groups have pushed back, arguing that regulators haven't given a good reason for why they need such detailed information.
The state's demand 'impermissibly violates the health privacy and security of millions of Floridians,' the American Benefits Council wrote to Florida Insurance Commissioner Mike Yaworsky in February.
The organization, which asked the state to withdraw its request, represents hundreds of the world's largest corporations. Many of its members use pharmacy benefit managers to manage their employees' health plans, but some are insurers and pharmacy benefit managers themselves.
Critics of pharmacy benefit managers said the concerns over patient privacy are reasonable.
But the Office of Insurance Regulation said the request was 'in the best interest to protect consumers.' Officials also lashed out at critics.
'These 'raised concerns' are clearly from those who do not want to be regulated or have any oversight in their industry,' a spokesperson told Bloomberg News, which first reported news of the request.
The office wrote that it has had no data breaches, while the health care industry was 'the most breached sector in 2024.' (Hackers stole HIV test results and other sensitive information on 729,699 Floridians at the Department of Health, a separate state agency, last year.)
Another industry trade group raised the prospect that the state is using the data to identify doctors providing illegal abortion services or transgender treatment for minors, but there is no evidence that's the case.
The Office of Insurance Regulation told the Herald/Times it requested the detailed information as it probes the pharmacy benefit manager industry for the first time, thanks to a 2023 law that gives the state more oversight.
Taking on pharmacy benefit managers has been a DeSantis priority. He touted the 2023 legislation as an appeal to seniors during his failed run for president that year.
The data requested by regulators under the new law could be used to uncover the workings of one of the most opaque parts of America's bloated medical system.
'It is important to be thorough in order to establish a baseline,' spokesperson Shiloh Elliott said in a statement.
Pharmacy Benefit Managers
Pharmacy benefit managers emerged in the 1960s when employee health plans began offering workers a new benefit: coverage for prescription drugs.
Before then, drugs were relatively cheap. Patients could get their prescriptions filled at nearly any pharmacy and pay out of pocket.
But when insurance plans began covering prescriptions, they turned to pharmacy benefit managers to process the claims and monitor the costs.
The benefit managers' purpose was to drive down costs by negotiating with pharmacies and drug makers to get the best prices for the insurer and its patients.
The industry's business model has changed drastically since then. Pharmacy benefit managers created their own pharmacies, merged with insurance companies and struck secret deals with drug manufacturers, driving up costs.
A New York Times investigation last year found that pharmacy benefit managers steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines and extract billions of dollars in hidden fees. Other state and federal regulators have made similar accusations in recent years as awareness of the industry has grown.
The three biggest pharmacy benefit managers are owned by CVS Health, Cigna and UnitedHealth Group and process 80% of all prescriptions in the United States.
'People keep calling them the middlemen,' said Antonio Ciaccia, president of 3 Axis Advisors, a consulting firm that investigates America's drug supply chain.
'They're the whole system at this point.'
Increasing oversight
DeSantis pushed the Legislature in 2023 to dramatically increase oversight of the industry. The law subjected pharmacy benefit managers in Florida to examinations every two years, starting in January this year.
It's not unusual for regulators to see patients' claim information. The Office of Insurance Regulation can already access detailed patient and doctor information for Medicaid recipients and employees on state health plans, for example.
But the state's data demand to pharmacy benefit managers goes well beyond that, to include self-insured plans that business groups say are protected by federal law.
'There's very clear Supreme Court authority that says the state can't do that,' said Ryan Temme, a lawyer for the American Benefits Council.
The organization is not seeking legal action to stop the requests, however.
Protecting Privacy
Corporations have used concerns over patient privacy to fight regulatory scrutiny. In the early 2000s, they argued that creating a database of doctors who prescribe opioids would violate the doctor-patient relationship. The database was eventually created and helped identify doctors and pharmacies abusing the system.
When then-Attorney General Ashley Moody asked for access to the data in 2019 to sue pharmacies and drug companies for those abuses, lawmakers initially resisted on similar grounds.
The data Moody received did not include patients' names or dates of birth. Patients were instead assigned random ID numbers.
Ciaccia's company analyzed 350 million anonymized Florida Medicaid claims to produce a 2020 report that found pharmacy benefit managers were paying their own pharmacies much more to dispense drugs than their competitors.
He said he didn't think it was critical for state regulators to have patients' names and birth dates.
'I don't think getting patient names is worth the trouble,' Ciaccia said.
Michael Jackson, a retired pharmacist and former CEO of the Florida Pharmacy Association, said concerns about privacy were fair.
'Any consumer would not want the government to have access to their confidential information,' Jackson said.
But as a former pharmacist who testified in support of Florida's 2023 legislation, he also questioned pharmacy benefit managers' motivations.
'What is it that the PBM industry doesn't want you to know?' Jackson said. 'Why are they hiding behind patient confidentiality?'
Herald/Times Tallahassee bureau reporter Alexandra Glorioso contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Hill
7 hours ago
- The Hill
CDC funding changes inject ‘chaos' into local health programs
The Trump administration has delayed or blocked millions of dollars in federal grants from the Centers for Disease Control and Prevention (CDC), leaving state and local health departments in the dark, uncertain when or even if they will get money that's already been appropriated by Congress for key public health initiatives. With little communication from the White House, CDC staff are trying to expedite getting grants out the door, and public health officials are scrambling to spend the money they have before it expires Sept. 30. The CDC typically doles out the money it receives from Congress to state and local health departments, which in turn fund local contracts. But with the start of the new administration, the White House began to apportion money to CDC on a month-by-month basis, citing the need for external reviews. That practice stopped when the agency received a two-month apportionment through the end of the fiscal year, according to CDC employees, but some grants were delivered late while others are still being blocked. 'Everything is weeks, if not months behind schedule,' a CDC employee with knowledge of the funding situation said. Another employee noted the extra layers involved in getting funding out the door, including new external reviews being conducted by the U.S. Department of Government Efficiency (DOGE). 'With every single award requiring DOGE review, there is fear the award may not be made before the end of the fiscal year and lapse of funds,' the employee said. Raynard Washington, director of the Mecklenburg County Public Health Department in North Carolina, said his agency laid off six workers — including half its disease investigators — after grants for HIV prevention and surveillance programs expired at the end of May with no information about future funding. The grants were eventually restored about a month later, but to date the department has only been able to bring back half of the people it laid off. 'So now we're behind, and cases are still being reported every day that have to be investigated,' Washington said. 'The more time that people may have been exposed to HIV and don't know it, or syphilis and don't know it and are getting tested and treated, those delays actually translate to potential illness.' Meanwhile, the Trump administration is preventing CDC from funding tens of millions of dollars in other awards, including for public health emergency preparedness, chronic disease prevention and education, academic prevention research centers, gun violence, and tobacco use. That means activities like training hospital staff and other health workers alongside first responders to prepare for a natural disaster are on hold. Washington said North Carolina had to lay off its team working on tobacco prevention efforts because the funding had dried up. 'These are not delays that we expect, given that Congress has appropriated funding for these initiatives,' Washington said. 'And these are things that — despite the political swings in Washington — have largely received bipartisan support, and so you don't expect that there was going to be gaps.' Philip Huang, director of Dallas County Health and Human Services in Texas, said he was waiting for nearly 30 percent of the promised award for public health emergency preparedness. The state doesn't know if that money is ever coming, Huang said. 'So, it makes it very difficult for us to plan. And many health departments don't have much buffer. If you plan and keep everything fully operational with all your staff now, and then you don't get the [remaining funding], then you're not going to be able to last through the year,' Huang said. CDC centers are currently not allowed to move funding into the blocked programs, according to employees. If that money is not apportioned by Sept. 30, it could be returned to the Treasury, a maneuver known as a 'pocket rescission' that has drawn criticism from lawmakers in both parties. Congress in July approved the White House's official rescissions proposal to claw back $9 billion of funding for foreign aid and public broadcasting. The White House would have to send another official rescission message to Congress, which Office of Management and Budget (OMB) Director Russell Vought claims would effectively freeze the funding and cause it lapse. 'Effectively, what they're doing is keeping that money in house. We can't pull it down,' said Scott Harris, chief of the Alabama Department of Public Health and president of the Association of State and Territorial Health Officials. 'We have grants that we thought we had access to, we suddenly have different rules about how we're allowed to spend.' Asked about the status of CDC grants, the Department of Health and Human Services referred The Hill to OMB, which did not respond to multiple requests for comment. Harris said the uncertainty is 'chaos' for health departments and makes it almost impossible to predict or plan for the future. 'We never really know month to month if a program's still going to be here anymore,' Harris said. 'We have serious concerns about whether all of the money that has been awarded will be spent before the end of the fiscal year. New instructions on which types of expenditures are allowable will prevent us from supporting much of the programmatic work that the grants are designed to fund.'
Yahoo
15 hours ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 hours ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data